AKYA vs. SEER, ATHA, PRE, RPID, PRLD, NAUT, STRO, PACB, MOLN, and PDSB
Should you be buying Akoya Biosciences stock or one of its competitors? The main competitors of Akoya Biosciences include Seer (SEER), Athira Pharma (ATHA), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Prelude Therapeutics (PRLD), Nautilus Biotechnology (NAUT), Sutro Biopharma (STRO), Pacific Biosciences of California (PACB), Molecular Partners (MOLN), and PDS Biotechnology (PDSB). These companies are all part of the "medical" sector.
Akoya Biosciences (NASDAQ:AKYA) and Seer (NASDAQ:SEER) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.
Akoya Biosciences received 25 more outperform votes than Seer when rated by MarketBeat users. Likewise, 60.87% of users gave Akoya Biosciences an outperform vote while only 14.29% of users gave Seer an outperform vote.
Akoya Biosciences has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500. Comparatively, Seer has a beta of 1.52, indicating that its stock price is 52% more volatile than the S&P 500.
In the previous week, Seer had 5 more articles in the media than Akoya Biosciences. MarketBeat recorded 8 mentions for Seer and 3 mentions for Akoya Biosciences. Akoya Biosciences' average media sentiment score of 1.42 beat Seer's score of 0.20 indicating that Akoya Biosciences is being referred to more favorably in the media.
Akoya Biosciences presently has a consensus price target of $7.79, indicating a potential upside of 245.26%. Seer has a consensus price target of $7.00, indicating a potential upside of 267.45%. Given Seer's higher probable upside, analysts plainly believe Seer is more favorable than Akoya Biosciences.
Akoya Biosciences has higher revenue and earnings than Seer. Akoya Biosciences is trading at a lower price-to-earnings ratio than Seer, indicating that it is currently the more affordable of the two stocks.
79.4% of Akoya Biosciences shares are held by institutional investors. Comparatively, 75.2% of Seer shares are held by institutional investors. 7.3% of Akoya Biosciences shares are held by company insiders. Comparatively, 15.0% of Seer shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Akoya Biosciences has a net margin of -72.68% compared to Seer's net margin of -529.52%. Seer's return on equity of -20.69% beat Akoya Biosciences' return on equity.
Summary
Akoya Biosciences beats Seer on 9 of the 17 factors compared between the two stocks.
Get Akoya Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for AKYA and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding AKYA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Akoya Biosciences Competitors List
Related Companies and Tools
